Search for contacts, projects,
courses and publications

ATAC - Antibody therapy against coronavirus (COVID-2019)

People

 

Varani L.

(Responsible)

Robbiani D.

(Co-responsible)

Abstract

Passive immunotherapy, through the transfer of antibodies, has been proposed as a potential approach for treating patients with COVID-19. Building on previous experience of antibody therapy against SARS- and MERS-CoV, scientists of the EU-funded ATAC project will characterise human antibodies obtained from the blood of recovered coronavirus patients from China and Italy. Using a combination of experimental and computational work, they will optimise, produce and test all antibodies before selecting the most effective candidate for therapy. The rapid dissemination of the project's results will help the medical community respond to the current COVID-19 pandemic through improved patient management.

Additional information

Acronym
ATAC
Start date
01.04.2020
End date
31.03.2022
Duration
24 Months
Funding sources
Status
Active
Category
European and International Programmes / Horizon 2020 / Collaborative projects - Societal Challenges